SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--
Exelixis, Inc. (EXEL) today announced that Michael M. Morrissey, Ph.D., the company’s president and chief executive officer, will present at the 25th Annual Piper Jaffray Healthcare Conference at 10:30 a.m. EST/7:30 a.m. PST on Tuesday, December 3, 2013 in New York. During the presentation, Dr. Morrissey will review the company’s development plans and priorities for cabozantinib. He will also discuss the company’s corporate strategy and financial outlook, and provide a general business update.
The presentation will be webcast and may be accessed via the Event Calendar page under Investors & Media at www.exelixis.com.
Exelixis, Inc. is a biotechnology company committed to developing small molecule therapies for the treatment of cancer. Exelixis is focusing its proprietary resources and development efforts exclusively on COMETRIQ® (cabozantinib). Exelixis has also established a portfolio of other novel compounds that it believes have the potential to address serious unmet medical needs, many of which are being advanced by partners as part of collaborations. For more information, please visit the company's web site at www.exelixis.com.
Exelixis, the Exelixis logo, and COMETRIQ are registered U.S. trademarks.
- Health Care Industry
- Investment & Company Information
Charles Butler, 650-837-7277
Vice President, Investor Relations and Corporate Communications